Evidence supporting the use of: Cysteine
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cysteine, particularly in the form of N-acetylcysteine (NAC), is used to support and treat Chronic Obstructive Pulmonary Disease (COPD) based on scientific evidence. NAC is a precursor to the amino acid cysteine and acts as a mucolytic agent, helping to break down mucus in the airways, which can improve airway clearance in individuals with COPD. In addition, NAC has antioxidant properties, replenishing intracellular glutathione and thereby reducing oxidative stress, a key aspect of COPD pathophysiology.

Clinical studies and several meta-analyses have investigated NAC’s effectiveness in COPD. Evidence suggests that regular use of oral NAC (typically 600–1200 mg/day) can modestly reduce the frequency and duration of COPD exacerbations, particularly in patients not already taking inhaled corticosteroids. Some studies report improvement in symptoms like cough and sputum production, although effects on lung function (such as FEV1) are generally limited. The European Respiratory Society and other professional guidelines acknowledge the potential role for NAC as an adjunct therapy in select COPD patients, especially those with frequent exacerbations.

However, evidence is mixed, and some large trials have shown only modest or inconsistent benefit. Overall, the scientific basis for cysteine (NAC) use in COPD is moderate, justifying a rating of 3 out of 5. It is not considered a primary therapy, but it is sometimes used as an adjunct in clinical practice.

More about Cysteine
More about Chronic Obstructive Pulmonary Disorder

Products containing Cysteine

We currently have no products on Vitabase that contain this ingredient.